Andreasen N - Search Results

1

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K. Olsson A, et al. Among authors: andreasen n. Clin Chem. 2005 Feb;51(2):336-45. doi: 10.1373/clinchem.2004.039347. Epub 2004 Nov 24. Clin Chem. 2005. PMID: 15563479 Clinical Trial.

2

Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Andreasen N, Blennow K. Andreasen N, et al. Peptides. 2002 Jul;23(7):1205-14. doi: 10.1016/s0196-9781(02)00056-6. Peptides. 2002. PMID: 12128078 Review.

3

Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Andreasen N, et al. Acta Neurol Scand Suppl. 2003;179:47-51. doi: 10.1034/j.1600-0404.107.s179.9.x. Acta Neurol Scand Suppl. 2003. PMID: 12603251 Clinical Trial.

4

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K. Sjögren M, et al. Among authors: andreasen n. Clin Chim Acta. 2003 Jun;332(1-2):1-10. doi: 10.1016/s0009-8981(03)00121-9. Clin Chim Acta. 2003. PMID: 12763273 Review.

5

Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients.

Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Möller HJ, Hampel H, Davidsson P, Blennow K. Olsson A, et al. Among authors: andreasen n. Exp Neurol. 2003 Sep;183(1):74-80. doi: 10.1016/s0014-4886(03)00027-x. Exp Neurol. 2003. PMID: 12957490 Clinical Trial.

6

Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease.

Zetterberg H, Andreasen N, Blennow K. Zetterberg H, et al. Among authors: andreasen n. Neurosci Lett. 2004 Sep 2;367(2):194-6. doi: 10.1016/j.neulet.2004.06.001. Neurosci Lett. 2004. PMID: 15331151

7

CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

Andreasen N, Blennow K. Andreasen N, et al. Clin Neurol Neurosurg. 2005 Apr;107(3):165-73. doi: 10.1016/j.clineuro.2004.10.011. Clin Neurol Neurosurg. 2005. PMID: 15823670 Review.

8

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E. Vanderstichele H, et al. Among authors: andreasen n. Clin Chem. 2005 Sep;51(9):1650-60. doi: 10.1373/clinchem.2005.051201. Epub 2005 Jul 14. Clin Chem. 2005. PMID: 16020497

9

An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid.

Portelius E, Zetterberg H, Andreasson U, Brinkmalm G, Andreasen N, Wallin A, Westman-Brinkmalm A, Blennow K. Portelius E, et al. Among authors: andreasen n. Neurosci Lett. 2006 Dec 6;409(3):215-9. doi: 10.1016/j.neulet.2006.09.044. Epub 2006 Oct 17. Neurosci Lett. 2006. PMID: 17049739

10

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, Zetterberg H. Ohrfelt A, et al. Among authors: andreasen n. Neurosci Lett. 2009 Feb 6;450(3):332-5. doi: 10.1016/j.neulet.2008.11.015. Epub 2008 Nov 12. Neurosci Lett. 2009. PMID: 19022350

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

632 results

Search Page

Filters